Sales & Marketing Evolving HCP access requires a new connected approach to bui... Specialty medicines – treatments designed for very small patient populations with complex and rare conditions – are on the rise.
R&D In conversation with Chris Moore: Declining HCP access During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
Market Access Shifting HCP access calls for new field tactics globally Even before COVID-19 pushed access to an all-time low, access had been declining
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends